Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

82.35
+1.251.54%
Post-market: 82.350.00000.00%18:28 EST
Volume:486.26K
Turnover:40.23M
Market Cap:1.85B
PE:-126.86
High:83.58
Open:81.37
Low:81.19
Close:81.10
52wk High:99.50
52wk Low:52.50
Shares:22.47M
Float Shares:20.38M
Volume Ratio:1.28
T/O Rate:2.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6491
EPS(LYR):-1.0429
ROE:8.66%
ROA:2.49%
PB:3.66
PE(LYR):-78.96

Loading ...

ANI Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Aug 08

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Aug 08

ANI Pharmaceuticals Shares Climb on Outlook Raise as Sales Surge

Dow Jones
·
Aug 08

ANI Pharmaceuticals Q2 Adjusted EPS USD 1.8 Vs. IBES Estimate USD 1.42

Reuters
·
Aug 08

Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance

Stock Track
·
Aug 08

Stock Track | ANI Pharmaceuticals Soars 6.49% Pre-market on Strong Q2 Results and Raised 2025 Guidance

Stock Track
·
Aug 08

GUIDANCE: (ANIP) ANI Pharmaceuticals Expects Full-Year 2025 Adjusted EPS Range $6.98 - $7.35, vs. FactSet Est of $6.53

MT Newswires Live
·
Aug 08

ANI Pharmaceuticals Q2 2025 Adj. EPS $1.80 Beats $1.39 Estimate, Sales $211.371M Beat $187.797M Estimate

Benzinga
·
Aug 08

ANI Pharmaceuticals Outlook FY Adjusted EPS USD 6.98-7.35

THOMSON REUTERS
·
Aug 08

ANI Pharmaceuticals Outlook 2025 Net Revenues $818-$843 Mln

THOMSON REUTERS
·
Aug 08

ANI Pharmaceuticals Outlook FY Adjusted Ebitda USD 213-223 Million

THOMSON REUTERS
·
Aug 08

ANI Pharmaceuticals Q2 Adjusted EPS USD 1.8 VS. Ibes Estimate USD 1.42

THOMSON REUTERS
·
Aug 08

ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance

GlobeNewswire
·
Aug 08

ANI Pharmaceuticals Inc expected to post earnings of $1.42 a share - Earnings Preview

Reuters
·
Aug 06

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

GlobeNewswire
·
Jul 30

ANI Pharmaceuticals' Iluvien to Treat Diabetic Macular Edema Fails to Meet Primary Endpoint in Trial

MT Newswires Live
·
Jul 23

BRIEF-Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)

Reuters
·
Jul 23

Meredith Cook, Sr. VP and General Counsel, Reports Disposal of ANI Pharmaceuticals Inc. Common Shares

Reuters
·
Jul 15

HC Wainwright Initiates ANI Pharmaceuticals at Buy With $84 Price Target

MT Newswires Live
·
Jul 10

ANI Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 10